Augment infrastructure to accelerate technology development, validation, and translation.
We build upon the existing research framework at the Biointerfaces Institute and invest in two research cores to aggressively develop and translate technologies that target brain cancer.
Formulation & Translation Core
The Formulation and Translation Core aims to reproducibly develop new drugs, nanoparticle formulations, and prototype devices within a sterile environment for subsequent animal testing. To ensure accurate dosing and sterility, the materials will undergo comprehensive characterization using multiple methodologies. Expert consultations will be conducted to assess the technology and market readiness, as well as determine the regulatory path for the developed innovations. The Core will perform exploratory pharmacokinetics, safety, and biocompatibility assessments of the new technologies. This Core will also focus on demonstrating the broad applicability of these technologies in delivering multiple drugs, establishing scalability in processes, and conducting reproducibility experiments.
Please visit the core page to learn more.
High-Plex Immunocytochemistry Core
The High-Plex Immunocytochemistry Core aims to conduct pharmacological evaluation of new technologies and therapeutic preclinical experiments in relevant brain tumor animal models, tumor microenvironment (TME) profiling, and tumor burden/progression and response to therapeutics. The High-Plex Immunocytochemistry Core features the Akoya PhenoCycler-Fusion to provide mapping of cell phenotypes for a variety of research purposes as characterizing tumor immune microenvironment changes in patient affected by brain cancer. The Core has optimized 52+ antibodies on multiple species and tissue types.
Please visit the core page to learn more.